Carbapenems and Monobactams

Carbapenems and monobactams are two further beta-lactam subclasses. Carbapenems carry a carbon in place of the usual ring sulfur and a distinctive trans hydroxyethyl side chain, giving them a broad spectrum and notable stability against many beta-lactamases. Monobactams, exemplified by aztreonam, have a monocyclic beta-lactam with no fused second ring and act selectively on aerobic Gram-negative bacteria.

Definition

Carbapenems are bicyclic beta-lactams with a carbapenem nucleus and broad, beta-lactamase-stable activity; monobactams are monocyclic beta-lactams active mainly against aerobic Gram-negative bacteria. Both inactivate penicillin-binding proteins via the shared beta-lactam mechanism.

Scope

This topic covers the structural features of carbapenems and monobactams, the basis of the carbapenems' broad spectrum and beta-lactamase stability, the narrow Gram-negative focus of monobactams, and the emergence of carbapenemase-mediated resistance. It is a reference overview without prescribing guidance.

Core questions

• What structural features give carbapenems their broad spectrum and beta-lactamase stability?
• Why is aztreonam's activity largely confined to aerobic Gram-negative bacteria?
• What are carbapenemases and why do they matter?

Key concepts

• Carbapenem nucleus
• Trans hydroxyethyl side chain
• Monocyclic beta-lactam
• Aztreonam
• Broad-spectrum activity
• Beta-lactamase stability
• Carbapenemases
• Reserve (last-resort) agents

Mechanisms

Both subclasses inactivate penicillin-binding proteins through the common beta-lactam mechanism. The carbapenems' replacement of the penam sulfur with carbon and their trans hydroxyethyl side chain confer unusual stability to hydrolysis by most serine beta-lactamases and a broad spectrum spanning many Gram-positive, Gram-negative and anaerobic organisms, which has made them important reserve agents (Papp-Wallace et al., 2011; Bush & Bradford, 2016). Monobactams lack a fused second ring; aztreonam binds preferentially to PBP3 of aerobic Gram-negative bacteria, accounting for its narrow spectrum and its stability to many beta-lactamases while sparing much of the Gram-positive and anaerobic flora. Resistance to carbapenems is driven largely by carbapenemase enzymes — including serine carbapenemases (e.g., KPC) and metallo-beta-lactamases (e.g., NDM-1) — often combined with porin loss (Walsh et al., 2011; Bush & Bradford, 2016).

Clinical relevance

Carbapenems are reference last-resort beta-lactams for serious infections, and monobactams illustrate how a single-ring beta-lactam can achieve a narrow, Gram-negative-focused profile; both are central to teaching antimicrobial stewardship and resistance. This entry describes the classes for educational orientation and is not a source of dosing or treatment recommendations.

Epidemiology

The spread of carbapenemase-producing Enterobacterales is a leading global resistance concern; the IDSA's ESKAPE framing highlighted carbapenem-resistant Gram-negative pathogens as a priority gap (Boucher et al., 2009), and the international dissemination of metallo-beta-lactamases such as NDM-1 underscored how rapidly carbapenem resistance can move across regions (Walsh et al., 2011).

Evidence & guidelines

Use and reporting of carbapenems and monobactams rely on standardized susceptibility testing and breakpoints from bodies such as EUCAST and CLSI, and surveillance of carbapenemase epidemiology informs stewardship priorities; this overview summarizes class properties rather than any specific guideline.

History

The carbapenems emerged from the natural product thienamycin, whose instability led to the development of imipenem and later, more stable agents such as meropenem (Papp-Wallace et al., 2011). The monobactams were developed around the naturally occurring monocyclic beta-lactam scaffold, yielding aztreonam as a Gram-negative-selective agent. Within decades, carbapenemases — including KPC and the metallo-enzyme NDM-1 — emerged and spread, eroding the carbapenems' reserve status (Walsh et al., 2011).

Key figures

• Krisztina Papp-Wallace
• Robert Bonomo
• Helen Boucher
• Timothy Walsh

Seminal works

• papp-wallace-2011
• walsh-2011-ndm

Frequently asked questions

Why are carbapenems often described as broad-spectrum reserve antibiotics?

Their carbapenem nucleus and side chain make them stable to most serine beta-lactamases and active against a wide range of bacteria, so they are frequently held in reserve for serious or resistant infections.

How does aztreonam differ from other beta-lactams?

Aztreonam is a monobactam with only a single beta-lactam ring; it acts selectively on aerobic Gram-negative bacteria and lacks meaningful activity against Gram-positive organisms and anaerobes.